ANGO
AngioDynamics Inc
15.40$
-0.6%
vs. previous close
Closing price · As of: Sep 17, 2026
Ownership
Ownership Structure
Who owns AngioDynamics Inc (ANGO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 76.9% of the shares are freely tradable; institutional investors hold 94.7%.
Institutional ownership
?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
94.7%
Insiders
?Share of the stock held by the executives, founders and major shareholders of the company itself.
12.3%
Float
?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
76.9%
Short % of float
?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
3.5%
Shares Outstanding
?Total number of shares issued. Price times share count gives market cap.
41Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 8.92 | 3,685,904 | -4.5 | 03/31/2026 |
| Point72 Asset Management, L.P. | 7.70 | 3,181,829 | +12.6 | 03/31/2026 |
| Systematic Financial Management LP | 5.94 | 2,453,701 | -2.0 | 03/31/2026 |
| Armistice Capital, LLC | 4.52 | 1,869,000 | +9.9 | 03/31/2026 |
| Broadfin Holdings LLC | 4.40 | 1,818,533 | -12.1 | 06/30/2026 |
| Vanguard Capital Management, LLC | 4.18 | 1,726,820 | +0.0 | 03/31/2026 |
| Royce & Associates, LP | 3.70 | 1,528,951 | +20.6 | 03/31/2026 |
| Weber Capital Management LLC | 3.28 | 1,356,602 | -1.2 | 06/30/2026 |
| State Street Corp | 3.23 | 1,333,858 | +4.8 | 03/31/2026 |
| Bastion Asset Management Inc. | 3.18 | 1,313,002 | +17.4 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Clemmer James C | President and CEO | 862,448 | 13,281,699 $ | Jul 22, 2026 | direct |
| Trowbridge Stephen A | EVP and CFO | 305,796 | 4,709,258 $ | Jul 22, 2026 | direct |
| Donnelly Howard W | Director | 178,938 | 2,755,645 $ | Jul 15, 2026 | direct |
| Johnson Wesley | Director | 155,425 | 2,393,545 $ | Jul 15, 2026 | direct |
| Reed Jan Stern | Director | 116,921 | 1,800,583 $ | Jul 15, 2026 | direct |
| Auen Eileen O'Shea | Director | 116,605 | 1,795,717 $ | Jul 15, 2026 | direct |
| Campbell Chad Thomas | SVP/GM, Vascular Access | 108,676 | 1,673,610 $ | Jul 22, 2026 | direct |
| Licitra Karen A | Director | 102,322 | 1,575,759 $ | Jul 15, 2026 | direct |
| Tarnoff Michael E | Director | 95,265 | 1,467,081 $ | Jul 15, 2026 | direct |
| Weiss Lawrence T | SVP, Chief Legal Officer | 91,330 | 1,406,482 $ | Jul 16, 2026 | direct |
| Piccinini Laura | SVP International | 81,929 | 1,261,707 $ | Jul 22, 2026 | direct |
| Burgess Lorinda | Director | 67,144 | 1,034,018 $ | Jul 15, 2026 | direct |
| Nighan Warren JR | SVP Quality and Regulatory | 64,745 | 997,073 $ | Jul 30, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | Nighan Warren JR | SVP Quality and Regulatory | Sell | 23,370 | 14.72 | 344,006 |
| Jul 22, 2026 | Piccinini Laura | SVP International | Other | 4,506 | 13.82 | 62,273 |
| Jul 22, 2026 | Piccinini Laura | SVP International | Other | 8,047 | 0.00 | – |
| Jul 22, 2026 | Nighan Warren JR | SVP Quality and Regulatory | Other | 1,671 | 13.82 | 23,093 |
| Jul 22, 2026 | Nighan Warren JR | SVP Quality and Regulatory | Other | 5,694 | 0.00 | – |
| Jul 22, 2026 | Trowbridge Stephen A | EVP and CFO | Other | 8,319 | 13.82 | 114,969 |
| Jul 22, 2026 | Trowbridge Stephen A | EVP and CFO | Other | 16,296 | 0.00 | – |
| Jul 22, 2026 | Clemmer James C | President and CEO | Other | 26,728 | 13.82 | 369,381 |
| Jul 22, 2026 | Clemmer James C | President and CEO | Other | 52,358 | 0.00 | – |
| Jul 22, 2026 | Campbell Chad Thomas | SVP/GM, Vascular Access | Other | 2,330 | 13.82 | 32,201 |
| Jul 22, 2026 | Campbell Chad Thomas | SVP/GM, Vascular Access | Other | 6,466 | 0.00 | – |
| Jul 20, 2026 | Trowbridge Stephen A | EVP and CFO | Other | 717 | 13.71 | 9,830 |
| Jul 20, 2026 | Piccinini Laura | SVP International | Other | 616 | 13.71 | 8,445 |
| Jul 20, 2026 | Nighan Warren JR | SVP Quality and Regulatory | Other | 251 | 13.71 | 3,441 |
| Jul 20, 2026 | Clemmer James C | President and CEO | Other | 4,223 | 13.71 | 57,897 |
| Jul 20, 2026 | Campbell Chad Thomas | SVP/GM, Vascular Access | Other | 359 | 13.71 | 4,922 |
| Jul 19, 2026 | Clemmer James C | President and CEO | Other | 487 | 13.51 | 6,579 |
| Jul 19, 2026 | Clemmer James C | President and CEO | Other | 11,764 | 13.51 | 158,932 |
| Jul 17, 2026 | Trowbridge Stephen A | EVP and CFO | Other | 3,510 | 13.51 | 47,420 |
| Jul 17, 2026 | Piccinini Laura | SVP International | Other | 3,074 | 13.51 | 41,530 |
| Jul 17, 2026 | Nighan Warren JR | SVP Quality and Regulatory | Other | 1,373 | 13.51 | 18,549 |
| Jul 17, 2026 | Clemmer James C | President and CEO | Other | 10,649 | 13.51 | 143,868 |
| Jul 17, 2026 | Campbell Chad Thomas | SVP/GM, Vascular Access | Other | 1,112 | 13.51 | 15,023 |
| Jul 16, 2026 | Weiss Lawrence T | SVP, Chief Legal Officer | Other | 2,267 | 14.14 | 32,055 |
| Jul 16, 2026 | Trowbridge Stephen A | EVP and CFO | Other | 7,840 | 14.14 | 110,858 |
| Jul 16, 2026 | Piccinini Laura | SVP International | Other | 4,538 | 14.14 | 64,167 |
| Jul 16, 2026 | Nighan Warren JR | SVP Quality and Regulatory | Other | 2,153 | 14.14 | 30,443 |
| Jul 16, 2026 | Clemmer James C | President and CEO | Other | 18,588 | 14.14 | 262,834 |
| Jul 16, 2026 | Campbell Chad Thomas | SVP/GM, Vascular Access | Other | 2,367 | 14.14 | 33,469 |
| Jul 15, 2026 | Reed Jan Stern | Director | Other | 11,887 | 0.00 | – |
| Jul 15, 2026 | Licitra Karen A | Director | Other | 11,887 | 0.00 | – |
| Jul 15, 2026 | Johnson Wesley | Director | Other | 11,887 | 0.00 | – |
| Jul 15, 2026 | Donnelly Howard W | Director | Other | 11,887 | 0.00 | – |
| Jul 15, 2026 | Burgess Lorinda | Director | Other | 11,887 | 0.00 | – |
| Jul 15, 2026 | Auen Eileen O'Shea | Director | Other | 11,887 | 0.00 | – |
| Jul 15, 2026 | Tarnoff Michael E | Director | Other | 11,887 | 0.00 | – |
| Jul 15, 2026 | Trowbridge Stephen A | EVP and CFO | Other | 53,257 | 0.00 | – |
| Jul 15, 2026 | Piccinini Laura | SVP International | Other | 19,860 | 0.00 | – |
| Jul 15, 2026 | Nighan Warren JR | SVP Quality and Regulatory | Other | 17,966 | 0.00 | – |
| Jul 15, 2026 | Campbell Chad Thomas | SVP/GM, Vascular Access | Other | 16,081 | 0.00 | – |
| Jul 15, 2026 | Weiss Lawrence T | SVP, Chief Legal Officer | Other | 21,288 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.